胸腔积液CEA、CA125检测对非小细胞肺癌预后判断的价值

High Level of CEA and CA125 in Pleural Fluid Correlates with Poor Survival in NSCLC Patients with Malignant Effusions

目的探讨胸腔积液中癌胚抗原(CEA)和癌抗原125(CA125)在恶性胸腔积液非小细胞肺癌(NSCLC)的预后价值。方法共有75例确诊恶性胸腔积液NSCLC患者被归纳入本研究,通过ELISA方法检测胸腔积液标本的CEA和CA125水平。结果 NSCLC胸腔积液中CEA≥100ng/ml或CA125≥1000U/ml患者中位生存时间有所缩短,但都不能作为独立的预后因素(P>0.05)。而胸腔积液中CEA≥100ng/ml和CA125≥1000U/ml的患者中位生存时间有更显著缩短(4.0个月vs 8.5个月,P<0.05)。结论 NSCLC患者恶性胸腔积液中CEA和CA125同时升高可作为一个独立的预后因素,对指导晚期NSCLC个体化治疗有着重要意义。

To determine whether CEA and CA125, either alone or in combination, could be used to predict survival time of patients with malignant pleural effusion due to advanced non - small cell lung cancer （ NSCLC）. Methods Seventy - five ehe- monaive patients with NSCLC malignant pleural effusion had been enrolled. Plcural fluid tumor markers were evaluated by enzyme - linked immuno sorbent assay. Results In patients with malignant effusion, CEA or CA125 cannot remained as an independent predictor of poor outcome. However, the combination of CEA ≥ 100ng/ml and CA125 ≥ 1000U/ml predicted a lower survival （4.0 vs 8.5 months, P 〈 0. 05 ）. Conclusion The combination of pleural fluid CEA and CA125 can remain as an independent predictor of poor outcome in NSCLC patient with malignant pleural effusion, which can provide individualized treatment strategy for advanced NSCLC patients.